跳至主要内容
临床试验/NCT03992794
NCT03992794已完成不适用

ADAPTED: Assessment of Disease Severity, Progression and Treatment in Infected Patients Presenting to the Emergency Department

Juan González-del Castillo3 个研究点 分布在 1 个国家目标入组 684 人开始时间: 2018年3月15日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
684
试验地点
3
主要终点
Mortality

研究概览

简要总结

The results of the SIDED study (doi: 10.1186 / s13054-019-2329-5) showed that MR-proADM can be a good biomarker to establish the prognosis of patients attended in the emergency department (ED) due to suspected infection. MR-proADM could be useful to help making-decision regarding admission or discharge of patients, and in addicion to determine the need to apply or not early antibiotic treatment. However, despite analyzing more than 2,500 patients from 8 countries, the original study had a number of limitations. Samples of the biomarkers were retrospectively analyzed in a device that is not routinely used in the ED (Kryptor, Thermo Fisher, Germany). The availability of MR-proADM at the point of care could facilitate its widespread use in all EDs. This study is conducted to confirm the results of the SIDED study by using a device at the patient's bedside that allows the quantitative determination of the MR-proADM and procalcitonin biomarkers, instead of using a Kryptor platform.

详细描述

Despite significant improvements in diagnostic and preventative measures, the incidence of sepsis has continued to escalate rapidly in hospitalized patients, with mortality rates ranging between 10 - 54%, depending on the level of severity. The earliest possible identification and assessment of sepsis patients entering the Emergency Department (ED) is therefore crucial in providing the patient with the most appropriate management and treatment strategy at the earliest time point possible. Indeed, an early identification of patients with an infection and at a high risk of cardiovascular and organ dysfunction can lead to an earlier individualised treatment, a potential reduction in the number of clinical complications, and an overall decrease in hospital mortality.

Adrenomedullin (ADM), a 52 amino acid peptide, is a member of the calcitonin peptide family and is widely expressed in many tissues and organs, although its main sources of production include the endothelial and vascular smooth muscle cells. Adrenomedullin can act as both a hormone and cytokine (often termed a "hormokine") in an autocrine and paracrine manner, and its potent vasodilatory and hypotensive response is elicited through an initial increase in cyclic adenosine monophosphate levels, and a subsequent production of nitric oxide.

The importance of adrenomedullin in homeostasis is illustrated by its central role in the up- and down-regulation of cytokines and other mediators, as well as its own stimulatory and inhibitory effect on cytokine production. Indeed, Interleukin (IL)-1β and tumour necrosis factor (TNF) are two of the most potent stimulators for adrenomedullin production and adrenomedullin itself is up-regulated by hypoxia, bacterial products and shear stress, amongst many other factors.

Finally, adrenomedullin has been shown to have a variety of physiological functions, including immune-modulating, direct bactericidal, diuretic and potent vasodilatory activity, and in healthy conditions, circulates at low picomolar concentrations. However, plasma levels are significantly up-regulated in many diseased states in proportion to disease severity such as hypertension, renal failure, lower respiratory diseases and septic shock, due to either damage to the endothelial cells or microvascular and microcirculatory impairment.

This allows clinicians to determine the patients most at risk of developing complications upon their admission to the ED or ICU, in order to rapidly triage and administer the most effective treatment, in the shortest space of time.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • Consecutive patients presenting to the ED with either a suspected or documented infection
  • Blood samples taken during routine use only
  • Patient has given written informed consent

排除标准

  • Age < 18 years
  • Patients where no blood samples were taken for routine purposes
  • Those with no suspicion of infection
  • Pregnancy
  • Refusal to participate
  • Patient has already participated in a similar clinical trial

结局指标

主要结局

Mortality

时间窗: 28 days

Mortality

ICU admission

时间窗: 28 days

Intensive care admission of the attended patient

Time of antibiotic administration

时间窗: 24 hrs

Length of time from initial presentation at the ED to the first dose of antibiotics being administered.

次要结局

  • Disease progression(28 days)
  • Hospital readmission(28 days)

研究者

发起方
Juan González-del Castillo
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Juan González-del Castillo

HEAD OF INFECTION DISEASE GROUP OF SPANISH EMERGENCY MEDICINE SOCIETY

Sociedad Española de Medicica de Emergencias

研究点 (3)

Loading locations...

相似试验